Shanghai's Phagelux Raises $10 Million for Anti-Bacterial Phages

Phagelux, a Shanghai anti-bacterial company, announced a $10 million funding from existing and new institutional investors. The company is developing anti-bacterial products for human and agricultural health using phage and phage-based technologies. Phages are potential alternatives to many uses of antibiotics, including drug-resistant bacteria strains. Phagelux said it is close to commercialization of its first marketed products. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.